An improved understanding of immune mechanisms in cancer has informed productive interventions using combination therapies. However, with multiple agents, toxicities become increasingly prevalent and severe thereby hindering these treatments from reaching their full curative potential. Particularly now during an era of combination immunotherapy, there is a pressing need to develop a safe and efficacious delivery platform for immunotherapies. Improving the therapeutic index amounts to better localizing the effects of immunomodulatory agents to the tumor. To this end, we intend to develop a platform for intratumoral localization of immunomodulatory payloads via fusion to extracellular matrix-binding modules.